A Cytokine-Delivering Polymer Is Effective in Reducing Tumor Burden in a Head and Neck Squamous Cell Carcinoma Murine Model

Abstract

Objective

This study aimed to evaluate the therapeutic efficacy of a novel polymer platform delivering cisplatin and cytokines in the treatment of head and neck squamous cell carcinoma (HNSCC).

Study Design

In vivo study.

Setting

Academic research laboratory.

Subjects and Methods

Mice were randomized to receive implantation of (1) no polymer, (2) plain polymer, (3) plain polymer with local cisplatin injection, or (4) cisplatin polymer. The 2 groups of mice implanted with cisplatin polymer or no polymer were further randomized to receive (1) 4 Grays external beam radiation for 4 days or (2) no radiation. For cytokine studies, mice were grouped into (1) no polymer, (2) plain polymer, (3) plain polymer with intratumoral injection of recombinant CCL21 twice a week, (4) polymer containing parental dendritic cells, or (5) polymer containing dendritic cells secreting CCL21 (DC-CCL21).

Results

The cisplatin-secreting polymer effectively reduced tumors in the mice by more than 16-fold (P < .01). We also observed a statistically significant lower tumor weight among mice treated with cisplatin polymer and concomitant radiation compared to control groups. The DC-CCL21 polymer reduced SCCVII/SF tumors in the C3H/HeJ mice by more than 41% (P < .01).

Conclusion

Herein, we demonstrate the efficacy of a novel polymer platform in delivering cisplatin and cytokines. We also demonstrate that we can effectively grow dendritic cells in the polymer that can actively secrete CCL21 for a minimum of 5 days. This polymer may represent a new therapeutic modality for patients with HNSCC. Once this polymer platform is optimized, we will plan to pursue prospective trials in patients with HNSCC.

Keywords

head and neck cancer squamous cell carcinoma polymer novel therapeutics

Get full access to this article

View all access options for this article.

References

Ferlay

Bray

Pisani

. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide [computer program]. Version 1.0. Geneva, Switzerland: World Health Organization; 2001.

Shikani

Domb

. Polymer chemotherapy for head and neck cancer. Laryngoscope. 2000;110:907-917.

Ross

Hundal

Son

. Microsurgical free flap reconstruction outcomes in head and neck cancer patients after surgical extirpation and intraoperative brachytherapy. Laryngoscope. 2004;114:1170-1176.

Xian

Yang

Lin

. Combination nonviral murine interleukin 2 and interleukin 12 gene therapy and radiotherapy for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2005;131:1079-1085.

Domb

, ed. Polymeric Site-Specific Pharmacotherapy. New York, NY: John Wiley; 1994.

Domb

Kost

Wiseman

, eds. Handbook for Biodegradable Polymers. Amsterdam, Netherlands: Harwood Academic Publishers; 1997.

Cohen

Ding

Kessinger

Khemtong

Gao

Sumer

. Polymeric micelle nanoparticles for photodynamic treatment of head and neck cancer cells. Otolaryngol Head Neck Surg. 2010;143:109-115.

Lau

Wang

. A novel modular polymer platform for the treatment of head and neck squamous cell carcinoma in an animal model. Arch Otolaryngol Head Neck Surg. 2012;138:412-417.

Mandpe

Tsung

Norton

. Cure of an established nonimmunogenic tumor, SCC VII, with a novel interleukin 12–based immunotherapy regimen in C3H mice. Arch Otolaryngol Head Neck Surg. 2003;129:786-792.

10.

Yoshida

Nagira

Kitaura

Imagawa

Imai

Yoshie

. Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7. J Biol Chem. 1998;273:7118-7122.

11.

Scheller

Krebsbach

. Gene therapy: design and prospects for craniofacial regeneration. J Dent Res. 2009;88:585-596.

12.

Kuriakose

Chen

Egilmez

. Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/SCID mouse model. Head Neck. 2000;22:57-63.

13.

Wang

. Sequential Layer Polymer Deposition [master’s thesis]. Los Angeles, CA: UCLA Biomedical Engineering; 2010.

14.

O’Malley

Jr Cope

Johnson

. A new immunocompetent murine model for oral cancer. Arch Otol. 1997;123:20-24.

15.

Stuschke

Pottgen

. Altered fractionation schemes in radiotherapy. Front Radiat Ther Oncol. 2010;42:150-156.

16.

Deurloo

Kop

van Tellingen

Bartelink

Begg

. Intratumoural administration of cisplatin in slow-release devices: II. Pharmacokinetics and intratumoural distribution. Cancer Chemother Pharmacol. 1991;27:347-353.

17.

Ning

Brown

Kanekal

Knox

. Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system. Radiother Oncol. 1999;2:215-223.

18.

Göpferich

. Mechanisms of polymer degradation and erosion. Biomaterials. 1996;17:103.

19.

Conley

Luck

. Response of murine tumors to matrix-associated cisplatin intratumoral implants. NCI Monogr. 1988;6:137-140.

20.

Vikram

Mishra

. Permanent iodine-125 implants in postoperative radiotherapy for head and neck cancer with positive surgical margins. Head Neck. 1994;16:155-157.

21.

Jewett

Cacalano

Teruel

. Inhibition of nuclear factor kappa B (NFkappaB) activity in oral tumor cells prevents depletion of NK cells and increases their functional activation. Cancer Immunol Immunother. 2006;55:1052-1063.

22.

Wang

Hunt

. Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res. 2004;64:1861-1866.

23.

Wang

Seethala

Zhang

. Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy. J Natl Cancer Inst. 2008;100:502-512.

24.

Haessler

Pisano

Swartz

. Dendritic cell chemotaxis in 3D under defined chemokine gradients reveals differential response to ligands CCL21 and CCL19. Proc Natl Acad Sci U S A. 2011;108:5614-5619.

25.

Christopherson

II Campbell

Hromas

. Transgenic overexpression of the CC chemokine CCL21 disrupts T-cell migration. Blood. 2001;98:3562-3568.

26.

Somanchi

Cooper

Lee

. Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood. 2012;119:5164-5172.

27.

Marcenaro

Cantoni

Pesce

. Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction. Blood. 2009;114:4108-4116.

28.

Le Maux Chansac

Moretta

Vergnon

. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol. 2005;175:5790-5798.

29.

Sofi

Wei

. MHC class II-expressing thymocytes suppress invariant NKT cell development. Immunol Cell Biol. 2009;87:186-189.

30.

Sharma

Yang

Hillinger

. SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer. 2003;2:22.

31.

Sharma

Stolina

Luo

. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol. 2000;164:4558-4563.

32.

Sharma

Stolina

Zhu

. Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 2001;61:6406-6412.

33.

Yang

Batra

Hillinger

. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 2006;66:3205-3213.

34.

Vicari

Ait-Yahia

Chemin

Mueller

Zlotnik

Caux

. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol. 2000;165:1992-2000.

35.

Arenberg

Zlotnick

Strom

Burdick

Strieter

. The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model. Cancer Immunol Immunother. 2001;49:587-592.